7 February 2023 - The decision from the MHRA will enable eligible individuals from the UK, who are travelling to dengue endemic regions, to benefit from a vaccine that has the potential to offer protection against dengue illness and hospitalisation, regardless of an individual's previous dengue exposure.

Takeda today announced that the MHRA has granted marketing authorisation for Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]), for active immunisation against dengue infection in individuals from four years of age.

Read Takeda press release